Zacks Investment Research cut shares of Mateon Therapeutics (OTCMKTS:MATN) from a buy rating to a hold rating in a research note published on Thursday morning.
According to Zacks, “Mateon Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents for the treatment of cancer. Its product pipeline consists of VDAs-CA4P and OXi4503, which are in preclinical trail stage. Mateon Therapeutics, Inc., formerly known as OXiGENE, Inc., is based in SOUTH SAN FRANCISCO, United States. “
Separately, HC Wainwright lowered shares of Mateon Therapeutics from a buy rating to a neutral rating in a research note on Friday, August 17th.
Mateon Therapeutics (OTCMKTS:MATN) last posted its quarterly earnings data on Tuesday, August 14th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.02. On average, analysts expect that Mateon Therapeutics will post -0.08 earnings per share for the current fiscal year.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia.
Read More: What is the float in trading stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.